Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $1.1552W HIGH $10.68
Volume
1.17 M
Value Traded
11.11 M
Short % Float
28%
Days to Cover
3.5
+31.5%Week
-12.57%1 Month
-66.33%3 Month
-52.56%6 Month
-58.49%5 Year
-58.49%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
120.40 M
EPS (TTM)
-0.16
P/E Ratio
-
Ent. Value
155.60 M
Total Shares
72.10 M
Float Shares
10.54 M
Insiders
85.38%
Institutions
20.10%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
PoA blends historical approval base rates, trial design score and FDA review track record.
AIRS Catalyst Timeline
Dated clinical, regulatory and corporate events for AirSculpt Technologies, Inc.
Past FDA Catalysts and PDUFA Decisions
How AIRS actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| No matching catalysts | ||||||
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
AirSculpt Technologies, Inc. is a medical device company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every AIRS program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Feinstein Adam TDirector, 10% Owner | Other | -5,169,820 6,591,642 held | $0.00 | 05/20/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in AIRS
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Ikarian Capital, LLC | 0 % | 73.79 K | 16.40 K |
Ownership Trends
AIRS Short Interest
Shares sold short, counted twice a month.
28%
Short % of Float
of tradable shares sold short
3.0M
Shares Sold Short
-1.7% vs prior count
3.5 Moderate
Days to Cover
trading days of normal volume to buy every short share back
855.2K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How AIRS ranks across every disease it competes in
Competitive Position is a premium feature
See how AIRS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialAIRS News
AIRS▲ +1.4%today
AirSculpt Technologies Announces Earnings Release Date, Conference Call, and Webcast for Third Quarter Fiscal 2026 Results
AirSculpt Technologies, Inc. will release its third quarter 2026 financial results on November 6, 2026. A conference call will follow at 8:30 a.m. Eastern Time. Investors can access the call via phone or a live webcast. The company specializes in minimally invasive body contouring procedures.
Read more →AIRS▼ -45.1%on this news
AirSculpt Technologies Reports Second Quarter Fiscal 2026 Results
AirSculpt Technologies reported its second quarter results for fiscal 2026, showing a 1% increase in same center case volume. However, revenue fell by 3% to $42.9 million, and the net loss widened to $1.1 million. The company reaffirmed its full-year revenue guidance at the lower end of its range, while reducing its adjusted EBITDA outlook.
Read more →AIRSAirSculpt Technologies Announces Earnings Release Date, Conference Call, and Webcast for Second Quarter Fiscal 2026 Results
AirSculpt Technologies will release its second quarter 2026 financial results on August 10, 2026. A conference call will follow at 8:30 a.m. Eastern Time. Additionally, the company will participate in Canaccord Genuity's 46th Annual Growth Conference on August 11, 2026, with a presentation scheduled for 4:30 p.m.
Read more →AIRSAirSculpt Technologies Announces Participation in Upcoming Investor Conferences
AirSculpt Technologies, Inc. announced its participation in two upcoming investor conferences. The first is the TD Cowen 10th Annual Future of the Consumer Conference on June 3, 2026, followed by the Oppenheimer 26th Annual Consumer Growth & E-Commerce Conference on June 9, 2026. Management will host fireside chats and investor meetings at both events.
Read more →AIRS▲ +11.6%on this news· ran to +35% by day 3
AirSculpt Technologies Reports First Quarter Fiscal 2026 Results
AirSculpt Technologies announced its first quarter results for fiscal 2026, reporting a 1% increase in same center sales. The company achieved stabilization in revenue, holding flat at $39.4 million, and is reaffirming its full year guidance for revenue and adjusted EBITDA. Despite a net loss of $2.4 million, AirSculpt's performance reflects a solid foundation for future growth, with an optimistic outlook as they capitalize on enhanced marketing initiatives and operational strategies.
Read more →AIRS▲ +23.9%on this news
AirSculpt Technologies Announces Earnings Release Date, Conference Call, and Webcast for First Quarter Fiscal 2026 Results
AirSculpt Technologies will release its first quarter 2026 financial results on May 8, 2026. A conference call will follow at 8:30 a.m. ET. The company will also participate in the Wolfe Research Global Consumer Growth Conference and the LD Micro Invitational, hosting presentations and meetings with investors.
Read more →AIRSAirSculpt Technologies Reports Fourth Quarter and Full Year Fiscal 2025 Results
AirSculpt Technologies, Inc. reported its fourth quarter and full year fiscal results for 2025, highlighting a decline in case volume and revenue compared to the previous year. Despite these challenges, the CEO noted improvements in same-store sales and the company's adaptation of new strategies and team enhancements. The firm projects a modest revenue growth for 2026, indicating a cautious optimism for recovery while facing increased competition and financial challenges.
Read more →AIRSAirSculpt Technologies Announces Fourth Quarter and Fiscal Year 2025 Earnings Release Date and Conference Call
AirSculpt Technologies, Inc. will release its fourth quarter and fiscal year 2025 financial results on April 2, 2026. A conference call will follow at 8:30 a.m. Eastern Time. The company is known for its premium body contouring procedures, which emphasize comfort and precision.
Read more →AIRS▲ +51.6%on this news
AirSculpt Technologies Announces Its Intent to Delay the Filing of its Annual Report and Provides Business Update
AirSculpt Technologies announced its intent to delay the filing of its annual report. The company reported preliminary fiscal year 2025 revenue of $151.8 million and noted positive same-store sales in February 2026. Additionally, AirSculpt highlighted a strong balance sheet and improved liquidity.
Read more →AIRS▼ -23.8%on this news
AirSculpt Technologies Appoints Mike Doyle as Non-Executive Chairman of the Board
AirSculpt Technologies has appointed Mike Doyle as the Non-Executive Chairman of the Board. Doyle, who has over 30 years of experience in the healthcare sector, is recognized for his leadership in multi-center healthcare organizations. His appointment is intended to support AirSculpt's next phase of transformation as the company seeks new opportunities in the market. CEO Yogi Jashnani expressed confidence in Doyle's ability to create value for stakeholders.
Read more →AIRS▼ -41.7%on this news
AirSculpt Technologies Reports Third Quarter Fiscal 2025 Results
AirSculpt Technologies reported its third quarter fiscal 2025 results, noting a revenue decline of 17.8% to $35.0 million compared to the same quarter last year. Despite lower revenue and an increased net loss of $9.5 million, CEO Yogi Jashnani highlighted strong progress in growth initiatives and an improved outlook for same store sales. The company also successfully reduced its debt and remains focused on leveraging opportunities in the aesthetics market due to GLP-1 use. AirSculpt is set to update its full-year revenue guidance as it adjusts expectations for EBITDA.
Read more →AIRS▼ -10.5%on this news
AirSculpt Technologies Reports Second Quarter Fiscal 2025 Results
AirSculpt Technologies reported its second quarter fiscal 2025 results, highlighting a 14.1% decline in case volume and a 13.7% drop in revenue year-over-year. Despite these declines, the company narrowed its losses and reported increased consumer consultations, signaling potential for future growth. CEO Yogi Jashnani mentioned the introduction of new services and affirmed the company's annual guidance. Additionally, CFO Dennis Dean announced his upcoming retirement but committed to ensuring a smooth transition.
Read more →AIRSAirSculpt Announces Public Offering of Common
AirSculpt Technologies, Inc. has announced a public offering of 3,160,000 shares of its common stock, with an option for the underwriter to purchase an additional 474,000 shares. The proceeds are intended for debt repayment and general corporate purposes. Vesey Street Capital Partners has shown interest in buying up to $4 million in shares, but commitments are not binding. The offering may face market condition uncertainties that could affect its completion and may lead to shareholder dilution.
Read more →AIRS▲ +33.6%on this news
AirSculpt Technologies Reports First Quarter Fiscal 2025 Results and Full Year Guidance
AirSculpt Technologies, Inc. reported its first quarter fiscal 2025 results, highlighting a 17.9% decrease in case volume and a 17.3% decline in revenue. Despite these setbacks, CEO Yogi Jashnani expressed optimism about the company's new go-to-market strategy and ongoing cost reduction initiatives. The company anticipates improving revenue and EBITDA guidance for the full year 2025, projecting revenues between $160 and $170 million. AirSculpt believes in its long-term growth potential and plans to introduce new financing options and services to drive future performance.
Read more →AIRSAirSculpt Technologies Reports Fourth Quarter, and Full Year Fiscal 2024 Results
AirSculpt Technologies announced its fourth quarter and full year results for fiscal 2024, highlighting challenges such as a decline in case volume and revenue. The company reported a net loss of $8.3 million for the year and $5.0 million for the fourth quarter. CEO Yogi Jashnani outlined plans to stabilize sales performance and improve operations in 2025, despite anticipating a tough first quarter due to reduced marketing activities. The company is implementing a cost reduction program to enhance liquidity as it aims for a more profitable future.
Read more →AIRS▼ -19.9%on this news
AirSculpt Technologies Updates Fiscal Year 2024 Guidance in Advance of its Participation in the ICR Conference 2025
AirSculpt Technologies has updated its fiscal year 2024 guidance as it prepares to participate in the ICR Conference 2025. Newly appointed CEO Yogi Jashnani highlighted the company's potential for long-term growth through its proprietary technology and an asset-light business model. He emphasized the necessity of implementing operational changes and leveraging technology for improved decision-making. While optimistic about future performance, the company acknowledged potential risks associated with its guidance as it awaits year-end audits and results.
Read more →AIRS▲ +5.2%on this news
AirSculpt Technologies Names Yogi Jashnani Chief Executive Officer
AirSculpt Technologies Inc. has appointed Yogi Jashnani as its new Chief Executive Officer, effective January 7, 2025, taking over from Dennis Dean, who will remain as Chief Financial Officer. Jashnani, with a proven track record in driving revenue growth in the aesthetics and retail industries, aims to enhance operational efficiencies and expand market opportunities for AirSculpt. The company's innovative body contouring technology and effective consumer strategies serve as a solid foundation for its future growth.
Read more →AIRS▲ +20.7%on this news
AirSculpt Technologies Reports Third Quarter Fiscal 2024 Results Third Quarter Revenue of $42.5 million, Net Loss of $6.0 million and Adjusted EBITDA of $4.7 million
AirSculpt Technologies announced its third quarter fiscal 2024 results, reporting revenue of $42.5 million, down from $46.8 million in the same period last year, alongside a net loss of $6.0 million. Although the company opened four new centers and plans to maintain its revenue guidance for the year, challenges persist as case volume has declined by 4.3% from the previous year. The company aims to enhance lead conversions and improve margins while navigating ongoing market difficulties and potential risks tied to expansion and competition.
Read more →AIRS▲ +5.3%on this news· ran to +16% by day 3
AirSculpt Technologies Announces Preliminary Third Quarter 2024 Revenue Results
AirSculpt Technologies announced preliminary financial results for the third quarter of 2024, projecting revenue of approximately $42.5 million, a 9% decrease compared to the prior year. Despite the decline, the company reported an improvement in same-store cases. AirSculpt also announced it expects full-year revenue in the range of $183 million to $189 million, slightly adjusted from earlier guidance. The company has plans to maintain its Adjusted EBITDA outlook and will conduct an earnings call on November 8, 2024.
Read more →About AirSculpt Technologies, Inc.
Headquarters1111 LINCOLN ROAD, MIAMI BEACH, FL, 33139
Founded2012
BIOPHARMAWATCH ELITE PLUS
Trade the next AIRS catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime